Pluvicto May Slow Progression Earlier in Advanced Prostate Cancer
Treatment with Pluvicto following ARPI resulted in favorable progression and response outcomes in PSMA-positive mCRPR.
Source: curetoday.com
Xiaox Wei News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Xiaox Wei. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Xiaox Wei Today - Breaking & Trending Today
Metastatic Prostate Cancer Research: PSMAfore follow-on study favors radioligand therapy over change to androgen receptor pathway inhibition
Follow-on analysis of results from the phase 3 PSMAfore study, along with the overall study results, support the consideration of 177Lu-PSMA-617 as a new standa
Source: newswise.com
Prior Abiraterone Strengthens Outcomes With Lutetium Lu 177 Vipivotide Tetraxetan in mCRPC
Outcome improvements with lutetium Lu 177 vipivotide tetraxetan vs ARPI change favored prior treatment with abiraterone vs enzalutamide in mCRPC.
Source: onclive.com